Antisense suppresssion of protein kinase C-alpha and -delta in vascular smooth muscle

S J Busuttil1, D L Morehouse, J R Youkey

  • 1Department of Vascular Surgery and Sigfried and Janet Weis Center for Research, Geisinger Clinic, Danville, Pennyslvania 17822, USA.

Insights

Targeting protein kinase C (PKC) pathways is key for vascular disease. This study used antisense oligodeoxynucleotides to investigate PKC isozymes, finding PKCalpha downregulation minimally impacts MAPK activation, suggesting PKCdelta may play a role.

Area of Science:

  • Cellular and Molecular Biology
  • Vascular Biology
  • Signal Transduction

Background:

  • Vascular smooth muscle cell (VSMC) proliferation and gene expression are regulated by intracellular signaling pathways.
  • Protein kinase C (PKC) activation is central to growth factor signaling, leading to downstream mitogen-activated protein kinase (MAPK) activation.
  • PKC isozymes alpha and delta are predominant in rat aortic VSMC and can be downregulated by phorbol 12,13 dibutyrate (PDBu).

Purpose of the Study:

  • To investigate the role of specific PKC isozymes in regulating MAPK activation in VSMCs.
  • To assess the efficacy of isozyme-specific antisense oligodeoxynucleotides (ODNs) in manipulating PKC levels.
  • To understand the contribution of PKCalpha and PKCdelta to PDBu-induced MAPK activation.

Main Methods:

  • Downregulation of PKC isozymes in cultured rat aortic VSMC using prolonged PDBu stimulation.
  • Administration of isozyme-specific antisense ODNs (phosphorothioated, C-5 propynyl modified) complexed with Lipofectin.
  • Assessment of ODN uptake via FITC-labeling and optical imaging.
  • Measurement of PKC isozyme reexpression and MAPK activation in response to PDBu.

Main Results:

  • PKCalpha-specific antisense ODNs selectively inhibited PKCalpha recovery compared to nonsense ODNs (P < 0.001) without affecting PKCdelta recovery.
  • Despite significant PKCalpha downregulation, PDBu-induced MAPK activation was not significantly inhibited.
  • These findings suggest a minimal requirement of total PKCalpha for MAPK activation or a potential role for PKCdelta.

Conclusions:

  • Specific PKC isozymes can be selectively manipulated using antisense ODN technology in VSMCs.
  • PKCalpha may not be the sole mediator of PDBu-induced MAPK activation, with PKCdelta potentially playing a compensatory role.
  • This model system allows for the assessment of individual PKC isozyme roles in VSMC signaling, proliferation, and disease.

Related Concept Videos

Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...